info@strategicmarketresearch.com
26, Broadway, Suite 934, New York , 10004
us US: +1-315-636-4233    uk UK: +44-162-237-0614     in IN: +91-826-083-6500
smrlogonew
  • Home
  • About
    • Why SMR
    • Research Methodology
    • Media Coverage
    • Join Our Team
  • Reports
    • Aerospace and Defense
    • Agriculture
    • Automotive
    • Chemicals and Materials
    • Consumer Goods
    • Energy and Power
    • Equipment and Machinery
    • Food and Beverages
    • Healthcare
    • Information and Communication Technology
    • Semiconductor and Electronics
    • Manufacturing and Construction
  • Our Practices
    • Syndicated Research
    • Consulting Services
    • Custom Research
    • Full-time Engagement Model
  • Insights
    • Press Release
    • Blog
  • Contact
Home » Healthcare » Antibody Drug Conjugates Market Size, Global Report, 2030

Antibody Drug Conjugates Market By Application (Blood Cancer, Breast Cancer, Ovary Cancer, Lung Cancer, Skin Cancer, Brain Tumor, Other Applications), By Technology (Cleavable Linker, Non-cleavable Linker, Linker less), By Geography, Size, Share & Growth Forecast, 2021-2030

Published On: Jun-2022   |   Base Year: 2021   |   No Of Pages: 140   |   Historical Data: 2015 - 2019   |   Formats: PDF   |   Report ID: 93847854

Industry Report and Statistics (Facts & Figures) - Demand & Sales by Application & Technolgy

The global antibody drug conjugates market size was $4.00 Billion in 2021 and is predicted to reach $13.13 Billion by 2030, representing a CAGR of 14.12% during the forecast period 2021-2030.. North America is envisaged as the industry, with a share of around 37%, followed by Europe.

 

Conjugation covalently links prodrugs or drugs to natural or synthetic molecule carriers for the purpose of targeted usage, e.g polypeptides or proteins, lipids, polymers and carbohydrates. Conjugation has become a pivotal tool for drug release and targeted drug delivery of tiny molecules and biotherapeutic modalities, such as protein-drug conjugation, antibody-drug, polymer-drug conjugation and T-cell dual affinity re-targeting conjugation. Conjugating drugs to carriers can improve pharmacokinetics, drug stability, and pharmacodynamic properties and alter toxicity profiles. Antibody-drug conjugates or ADCs are a class of biopharmaceutical drugs formulated as a targeted therapy for treating and curing cancer. As compared to chemotherapy ADCs are used to target and vandalize tumour cells while sparing healthy cells. 

antibody drug conjugates market by share 2020-2030

Types of Antibody-based Cancer therapies:

The treatment uses antibodies to help the body fight cancer, infection, or other diseases. Antibodies are proteins made by the immune system bind to specific markers on cells or tissues. In recent years, antibody-based cancer therapy has emerged as one of the efficient therapeutic strategies.

Immune checkpoint inhibitors (ICIs):They block checkpoint proteins from binding with their partner proteins.

Angiogenesis inhibitors: They block the growth of blood vessels that support tumour growth.

Multi-specific antibodies Therapy: These are directed at multiple tumour antigens to eradicate tumour cells more precisely and effectively.

Chimeric antigen receptor T (CAR-T) cells therapy: T cells (a type of immune system cell) from the patient are altered in the lab to attack cancer cells.

Antibody drug conjugates (ADCs):They selectively deliver drugs to cancer cells by chemically joining monoclonal antibody that is chemically linked to a drug. 

Components of ADCs: An antibody-drug- conjugate consists of 3 components: 

Antibody: It targets the ADC and may also elicit a therapeutic response. 

Payload: It elicits the desired therapeutic response. 

Linker: It imparts high stability in the circulation and specific payload release in the target tissue.

 

Monoclonal antibodies targeted to surface antigens found on specific tumour cells are combined with highly effective anti-cancer drugs via a chemical linker in ADCs. The linker is a crucial component in the operation of ADCs because it connects the antibody to the cytotoxic payload.

 

 

Market Dynamics

Drivers (Increasing prevalence of cancer, High Incidence of breast cancer, High demand for Antibody-based Cancer therapies, Technological advancements , High risk in old age, Increase in an obese population and Increased research and clinical trials).

 

The Antibody Drug Conjugates Market Drivers Include:

  • Increasing prevalence of cancer: Cancer incidence grows with age, most likely due to an increase in the risk of certain tumours as people get older. The accumulation of risk is compounded by cellular repair systems becoming less effective as a person ages. The higher incidence of cancer is pulling the demand for ADCs. According to GLOBOCAN 2020, worldwide, an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths occurred in 2020.

 

  • High Incidence of breast cancer: The majority of approved ADCs are utilized for breast cancer patients. Age, obesity, hazardous alcohol use, family history of breast cancer, history of radiation exposure, reproductive history (first menstrual cycle age and first pregnancy age) and tobacco use, are all factors that raise the risk of breast cancer. Breast cancer has the highest incidence and the second-highest overall mortality rate among women in the United States, according to the American Cancer Society's cancer statistics.

 

  • High demand for Antibody-based Cancer therapies: The demand for various antibody-based cancer therapies is increasing due to their different mechanisms of action like natural properties, engagement of cytotoxic T cells, and delivery of cytotoxic payloads. According to an article published in the Antibody-drug Society, the commercial clinical pipeline of cancer therapies has become increasingly dominated by immune checkpoint modulators, antibody-drug conjugates (ADCs) and bispecific antibodies. Antibody-drug conjugates (ADCs) account for approximately 20% of the clinical pipeline of antibodies for cancer.

 

  • Technological advancements: The limited success of first-generation ADCs (developed in the early 2000s) paved the way to bring second-generation ADCs (2010 onwards) to the global antibody drug conjugates market, with higher cytotoxic drug conjugation levels, and lower levels of naked antibodies and more-stable linkers between the drug and the antibody. However, Third-generation ADCs (2019 onwards) use site-specific conjugation methods instead of random coupling, enabling strict control over payload conjugation to generate a homogeneous product.

 

  • High risk in old age: Advancing age is the most important risk factor for cancer and many individual cancer types. Cancer risk increases exponentially with age. According to research published in NCBI, about 60% of cancers occur in people 65 years of age or older. Furthermore, about 70% of the deaths caused by cancers occur in this stage.

 

  • Increase in an obese population: Obesity has been linked to worsening quality of life, cancer recurrence, cancer progression, prognosis (survival), and the chance of some "second primary cancers." Obesity in cancer survivors is mostly studied in people who have had breast, prostate, or colorectal cancer. As per the research done by the National Health And Nutrition Examination Survey (NHANES), 30.7% of adults are overweight, 42.4% have obesity, and About 9.2% of adults have severe obesity.

 

  • Increased research and clinical trials: ADCs have become an important class of anti-cancer drugs, with a dramatically increasing number of ADCs in clinical studies for treating hematologic malignancies and solid tumours over the past five years. According to NCBI, Nearly 60% (7 out of 12) of ADCs were approved by Food and Drug Administration in the past three years alone, indicating that the maturing of ADC technology brings more productive clinical outcomes. The recently approved ADCs include Polivy (2019), Padcev (2019), EnHertu (2019), Trodelvy (2020), Blenrep (2020), Zynlonta (2021), and Tivdak(2021).

 

Restraints (Stringent FDA guidelines and side effects)

  • Stringent FDA guidelines for the drug approval: A pharmaceutical firm must go through a five-step procedure to get FDA clearance to commercialize a new prescription drug: discovery/concept, preclinical research, clinical research, FDA review, and FDA post-market safety monitoring. According to the FDA Review Project, The FDA approval process is complex and time-consuming for drugs (9 to12 years) and devices(7 years).

 

  • Side-effects: Because of their great selectivity, ADCs have a manageable side-effect profile, with nausea and vomiting being the most common toxicities. However, this varies depending on the ADC and the accompanying payload. Fever, nausea, infection, vomiting, and stomatitis are other adverse effects. These serious adverse effects are low blood counts, liver damage, including hepatic veno-occlusive disease, infusion-related reactions (IRRs), and bleeding.

 

Opportunities 

Increase in product launches and approvals: The agency's Center for Drug Evaluation and Research (CDER) approved 50 novel therapeutics in 2021. The FDA's 5-year average approval count increased from 24 to 51 drugs per year in this decade. As per the article published in Science Direct, More than 80 ADCs have been investigated in different clinical stages from approximately 600 clinical trials. To date total of 12 ADCs have been approved by the FDA.

 

Rising old age population: Certain cancers are more common among the senior population. Some of the most common cancers like colon cancer and breast cancer are easily detected at nascent stages and are easily treatable. Other cancers, such as lung cancer, are more daunting to detect, and treatment can be more complex and crucial. The Rise in the old age population is likely to boost the demand for ADCs. According to World Bank data and World Population Prospects, The share of the old age population (65 years and more) will rise from 9.32% in 2020 to 16% by 2050. In the next 30 years, the number of people aged 65 and above will double, while those aged 80 and above will triple.

antibody drug conjugates market by application 2020-2030

Global Antibody Drug Conjugates Market Segments Analysis

The industry has been broadly bifurcated based on Application, Technology and Region.

By Application

  • Blood Cancer

  • Ovary Cancer

  • Breast Cancer

  • Skin Cancer

  • Lung Cancer

  • Brain Tumor

  • Other Applications

 

By Technology 

  • Non-cleavable Linker

  • Cleavable Linker

  • Linker less

 

By Region

North America

  • United States of America

  • Canada

  • Rest of North America

 

Europe

  • Spain

  • Germany

  • United Kingdom

  • Italy

  • Russia

  • France

  • Rest of Europe

 

Asia-Pacific

  • China

  • Japan

  • South Korea

  • Australia

  • India

  • Singapore

  • Rest of Asia-Pacific

 

LAMEA

  • Brazil

  • Argentina

  • South Africa

  • Saudi Arabia

  • United Arab Emirates

  • Rest of LAMEA

 

 

By Application, Breast Cancer dominates the segment due to increased patient awareness, growing breast cancer cases in females, technological advancements, and increased research and clinical trials. According to the fact sheet of the Food and Drugs Administration, the majority(25%) of approved ADCs (3 out of 12) were approved for breast cancer treatment.

 

By Technology, Cleavable Linker Technology Segment Accounted for Largest Revenue Share. With the awareness of plasma stability, greater therapeutic window, and higher stability and tolerability, Cleavable linkers are becoming more popular. Non-cleavable linkers are defined by higher stability in circulation and lower off-target activity which is due to its reduced "bystander effect" – killing antigen-negative cells. In contrast, cleavable linkers are accepted for their capability of being adapted to different usages and ability to exploit distinct mechanisms of action. According to the article published in Science Direct, More than 80% of the clinically approved ADCs employ cleavable linkers such as inotuzumabozogamicin (Besponsa) and brentuximabvedotin (Adcetris).

 

By Region, North America is poised to remain the antibody drug conjugates market, owing to the new product launches, rising frequency of cancer-related illnesses, active new drug pipeline projects, and significant industry players such as Pfizer, Inc., AstraZeneca, and Gilead Sciences. However, Asia-Pacific is poised to be the fastest growing industry.

 

 

Report Attribute

Details         

Forecast Period

2021-2030

Market size value in 2021

$4.00 Billion

Revenue forecast in 2030

$13.13 Billion

Growth rate

14.12%

Base year for estimation

2021

Historical data

2015-2019

Unit

USD Billion, CAGR (2021 - 2030)

Segmentation

By Application,By Technology and By Region

Based on Technology

Non-cleavable Linker,Cleavable Linker,Linker less

Based on Application

Blood Cancer,Ovary Cancer,Breast Cancer,Skin Cancer,Lung Cancer,Brain Tumor,Other Applications

By Region

U.S, Mexico, Canada and Rest of North America

Country Scope

U.S., Canada, France, Germany, U.K., China, Japan, India, South Korea, Mexico, Brazil, U.A.E. etc.

Company Usability Profiles

Takeda Pharmaceutical Company Ltd,Hoffmann-La Roche Ltd,Pfizer, Inc,AstraZeneca,Gilead Sciences, Inc,Seagen, Inc.Astellas Pharma

Forecast Period

2021-2030

 

 

Global Antibody Drug Conjugates Market Competitive Landscape Analysis

The Research Report has the competitive landscape analysis that highlights the companies operating in a industry. The comparison is based on overall revenue generation, market initiatives, company overview, production analysis, value chain optimization, industry share financials, production capacity, company strengths and weaknesses, global presence, production sites and facilities, and other variables.

  • Takeda Pharmaceutical Company Ltd.

  • Hoffmann-La Roche Ltd.

  • Pfizer, Inc.

  • AstraZeneca

  • Gilead Sciences, Inc. 

  • Seagen, Inc.

  • Astellas Pharma

  • Seagen, Inc.

  • Daiichi Sankyo Company Ltd.

  • GlaxoSmithKline Plc

  • ADC Therapeutics

 

Recent Developments

  • On June 2022, Roche successfully received the conditional approval from European Commission for mosunetuzumab/Lunsumio for the treatment of the patients suffering from follicular lymphoma who at least underwent therapies twice earlier.

 

  • On May 2022, Mersana Therapeutics announced the FDA approval of Orphan Drug Designation to XMT 2056 to treat gastric cancer.

 

  • On May 2022, ImmunoGen Inc. one of the industry leaders of ADC (Antibody-Drug Conjugates) in cancer treatment declared that it has successfully submitted a BLA (Biologics License Application) for receiving an FDA approval to launch its mirvetuximab soravtansine monotherapy in patients for the treatment of ovarian cancer. The PDUFA Date is scheduled for 28th Nov, 2022.

 

  • On March 2022, Seagen & Sanofi announced their collaboration for the development and commercialization of several antibody-drug conjugates. The main objective of this collaboration is to employ technologies used by both companies in manufacturing ADCs.

 

  • In February 2022, for sponsors interested in developing ADCs, the US FDA released draft guidance on clinical pharmacology concerns. This guidance provides recommendations to assist the industry and other parties in developing antibody-drug conjugates (ADCs). In several aspects of ADC clinical research, the agency advises sponsors to examine current advice. Bioanalytical methodologies, dosing regimens, dosage and exposure-response analyses, QTc assessments, immunogenicity, and drug-drug interactions (DDIs) are all covered in the guidelines.

 

  • In January 2022, ADC Therapeutics and Mitsubishi Tanabe Pharma Corporation signed an exclusive license agreement to develop and commercial loncastuximabtesirine (Zynlonta), a CD19-directed antibody-drug conjugate (ADC). Under the agreement terms, ADC Therapeutics will receive a US $ 30 million upfront payment and up to US $ 205 million in milestones and double-digit royalties based on net sales in Japan.

 

  • In September 2021, The FDA gave expedited approval to tisotumabvedotin-tftv, a tissue factor-directed antibody and microtubule inhibitor combination, for adult patients with recurrent or metastatic cervical carcinoma progressing on or after chemotherapy. The suggested dose is 2 mg/kg (up to 200 mg for individuals < 100 kg) given as a 30-minute intravenous infusion (IV therapy) every three weeks until the condition progresses or toxicity becomes unbearable.

 

  • In April 2021, ADC Therapeutics confirmed that it has received its 1st FDA clearance to launch ZYNLONTA. It is used to treat adult patients with refractory or relapsed large B cell lymphoma.

 

  • In May 2020, AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumabderuxtecan) was granted Breakthrough Therapy Designation (BTD) by FDA for treatment of patients with metastatic, HER2-mutated non-small cell lung cancer (NSCLC) after platinum-based therapy, and priority review for the treatment of HER2+ metastatic gastric or gastroesophageal junction adenocarcinoma. Breakthrough therapy designation is intended to expedite the development and review of drugs for serious or life-threatening conditions.

 

Various products that key market leaders develop

Product

Functions

Key Players

Mylotarg

(Gemtuzumabozogamicin)

For  Acute Myelogenous Leukemia treatment (AML)

Pfizer

Tivdak

(Tisotumabvedotin-tftv)

For recurrent or metastatic cervical cancer.

Seagen Inc

Kadcyla

(Trastuzumabemtansine )

For HER2-positive metastatic breast cancer.

Roche

 

Trodelvy

(Sacituzumabgovitecan)

For metastatic triple-negative breast cancer (mTNBC).

Immunomedics

Frequently Asked Question About This Report

The global antibody drug conjugates market size was $4.00 Billion in 2021 and is predicted to reach $13.13 Billion by 2030 with a CAGR of 14.12%.

The estimates foretell North America as the Antibody-drug Conjugate Market Leader.

Tumour-associated antigens (TAAs) are antigen molecules found on tumour cells or normal cells, such as embryonic proteins, glycoprotein antigens, squamous cell antigens, and others that have been utilized to treat a variety of cancers. For example, Melanoma-associated antigen (MAGE) is a protein found in the testes related to malignant melanoma.

ADCs are targeted medicines that release chemotherapy agents or cytotoxic drugs into the cancer cells. In addition to traditional cytotoxins, many payloads with new mechanisms are incorporated into ADC design. For example, Small molecule drug conjugate, Antibody-oligonucleotide conjugate and immune stimulating antibody conjugate are becoming significant in haematology and oncology.

The global antibody drug conjugates market is expected to grow at a compound annual growth rate (CAGR) of 14.12% from 2021 to 2030 to reach $13.13 Billion by 2030.

To date total of twelve ADCs have been approved by the FDA namely Brentuximabvedotin, Gemtuzumabozogamicin, Enfortumabvedotin, Inotuzumabozogamicin, Moxetumomabpasudotox, Polatuzumabvedotin, Loncastuximabtesirine, Belantamabmafodotin, Trastuzumabderuxtecan, Sacituzumabgovitecan, Trastuzumabemtansine, and Tisotumabvedotin-tftv.

.

1.   Introduction

       1.1. Study Objective

       1.2. Market Definition        

       1.3. Study Scope

              1.3.1. Markets Covered

              1.3.2. Geographic Scope

              1.3.3. Years Considered

              1.3.4. Stakeholders

2.   Research Methodology

       2.1. Data Procurement

       2.2. Paid Database

              2.2.1. Secondary Data

                     2.2.1.1. Key Secondary sources

              2.2.2. Primary Data

                     2.2.2.1 Primary sources

                2.2.2.2. Key industry insights

                     2.2.2.3. Primary interviews with experts

                     2.2.2.4. Key primary respondent list

       2.3. Market Size Estimation

       2.4. Bottom-Up and Top-Down Approaches

      2.4.1.             Bottom-Up Approach

                     2.4.1.1.         Approach for arriving at market size by bottom-up analysis

              2.4.2.     Top-Down Approach

                     2.4.2.1.         Approach for Capturing Market Size by Top-Down Analysis

       2.5. Market Breakdown and Data Triangulation

       2.6. Research Methodology

       2.7. Risk Assessment

3.  Executive Summary

       3.1  Antibody Drug Conjugates Market: Post-Covid-19

              3.1.1      Actual Scenario

              3.1.2      Pessimistic Scenario

              3.1.3      Optimistic Scenario

              3.1.4      Market Summary

4. Industry Outlook

       4.1  Market Snapshot

       4.2  Antibody Drug Conjugates Market

              4.2.1      Market, 2021-2030 (USD Million)

       4.3  Regional Business Analysis

              4.3.1      Market, by Region, 2021-2030 (USD Million)

       4.4  Product Type Business Analysis

              4.4.1      Market, By Application, 2021-2030 (USD Million)

       4.5  Procedure Business Analysis

              4.5.1      Market, By Technology, 2021-2030 (USD Million)

       4.6  Value Chain Analysis

       4.7  Market Variable Analysis

              4.7.1      Market Drivers Analysis

      4.7.2               Market Restraints Analysis

       4.8  Business Environment Analysis Tool

              4.8.1      Market PEST analysis

              4.8.2      Market Porter’s analysis

       4.9  Penetration & Growth Prospect Mapping

5. Market Dynamics

       5.1. Introduction

       5.2. Market Dynamics

              5.2.1.     Drivers

              5.2.2.     Restraints

              5.2.3.     Opportunities

              5.2.4.     Challenges

       5.3. Impact of Covid-19 On Market

       5.4. Value Chain Analysis

       5.5. Ecosystem

       5.6. Patent Analysis

       5.7. Trade Analysis

       5.8. Tariff Analysis

       5.9. Case Study Analysis

5.10.      Porter’s Five Forces Analysis

              5.10.1    Threat of New Entrants

              5.10.2    Threat of Substitutes

              5.10.3    Bargaining Power of Buyers

              5.10.4    Bargaining Power of Suppliers

              5.10.5    Degree of Competition

       5.11.              Technology Analysis

              5.11.1.   Trends in Technology (2014-2020)

              5.11.2.   Trends in Technology (2021-2028)

       5.12.              Pricing Analysis

              5.12.1.   Average Price Trend Analysis (By region, By Countries)

6. Competitive & Vendor Landscape

       6.1. Company Market Share Analysis

       6.2. Manufacturers Facial Implants Manufacturing Sites, Area Served, Product Type

       6.3. Market Competitive Situation and Trends

       6.4. Manufacturers Mergers & Acquisitions, Expansion Plans

7. Market: By Application Segment Analysis

       7.1. Introduction

       7.2. Sales Volume & Revenue Analysis (2021-2030)

       7.3. Blood Cancer

              7.3.1. Blood Cancer market, 2021-2030 (USD Million)

       7.4. Breast Cancer

              7.4.1. Breast Cancer market, 2021-2030 (USD Million)

       7.5. Ovary Cancer

              7.5.1. Ovary Cancer market, 2021-2030 (USD Million)

       7.6. Lung Cancer

              7.6.1. Lung Cancer market, 2021-2030 (USD Million)

       7.7. Skin Cancer

              7.7.1. Skin Cancer market, 2021-2030 (USD Million)

       7.8. Brain Tumor

              7.8.1. Brain Tumor market, 2021-2030 (USD Million)

       7.9. Other Applications

              7.9.1. Other Applications market, 2021-2030 (USD Million)

8. Market: By Technology Segment Analysis

       8.1. Introduction

       8.2. Sales Volume & Revenue Analysis (2021-2030)

       8.3. Cleavable Linker

              8.3.1. Cleavable Linker market, 2021-2030 (USD Million)

       8.4.Non-cleavable Linker

              8.4.1. Non-cleavable Linker market, 2021-2030 (USD Million)

       8.5 Linker less

              8.5.1 Linker less market, 2021-2030 (USD Million)

9. Market: Regional Outlook

9.1         North America

              9.1.1.     North America Market, By Application, 2021-2030 (USD Million)

 9.1.4.    North America Market, By Technology, 2021-2030 (USD Million)

 

9.1.5.     North America Market, by Country, 2021-2030 (USD Million)

9.1.4.1. U.S.

                     9.1.4.1.1.      U.S. Market, By Application, 2021-2030 (USD Million)

9.1.4.2.      Canada

9.1.4.2.1.             Canada Market, By Application, 2021-2030 (USD Million)

                     9.1.4.2.2.      Canada Market, By Region, 2021-2030 (USD Million)

                     9.1.4.2.3.      Canada Market, By Technologys, 2021-2030 (USD Million)

9.2.        Europe

              9.2.1.     Europe Market, By Application, 2021-2030 (USD Million)

              9.2.2.     Europe Market, by  By Technology, 2021-2030 (USD Million)

              9.2.5.     Europe Market, by country, 2021-2030 (USD Million)

9.2.4.1    U.K.

         9.2.4.1.1.   U.K. Market, By Application, 2021-2030 (USD Million)

                     9.2.4.1.2.      U.K. Market, By Technologys, 2021-2030 (USD Million)

                     9.2.4.1.3.      U.K. Market, by Region, 2021-2030 (USD Million)

9.2.4.2. Germany

                     9.2.4.2.1.      Germany Market, By Application, 2021-2030 (USD Million)

                     9.2.4.2.2.      Germany Market, By Technology, 2021-2030 (USD Million)

                     9.2.4.2.3.      Germany Market, by Region, 2021-2030 (USD Million)

9.2.4.3. France

                     9.2.4.3.1.      France Market, By Application, 2021-2030 (USD Million)

                     9.2.4.3.2.      France Market, By Region, 2021-2030 (USD Million)

   9.2.4.3.3.         France Market, By Technology, 2021-2030 (USD Million)

9.2.4.4. Rest of Europe

                     9.2.4.4.1.      Rest of Europe Market, By Application, 2021-2030 (USD Million)

   9.2.4.4.2.         Rest of Europe Market, By Region, 2021-2030 (USD Million)

                     9.2.4.4.3.      Rest of Europe Market, By Technology, 2021-2030 (USD Million)

       9.3. Asia Pacific

              9.3.1.     Asia Pacific Market, By Application, 2021-2030 (USD Million)

              9.3.2.     Asia Pacific Market, By Technology, 2021-2030 (USD Million)

       9.3.5.            Asia Pacific Market, by country, 2021-2030 (USD Million)

9.3.4.1. China

                     9.3.4.1.1.      China Market, By Application, 2021-2030 (USD Million)

                     9.3.4.1.2.      China Market, By Region, 2021-2030 (USD Million)

                     9.3.4.1.3.      China Market, By Technology, 2021-2030 (USD Million)

9.3.4.2. India

                     9.3.4.2.1.      India Market, By Application, 2021-2030 (USD Million)

                     9.3.4.2.2.      India Market, By Region, 2021-2030 (USD Million)

                     9.3.4.2.3.      India Market, By Technology, 2021-2030 (USD Million)

9.3.4.3. Japan

                     9.3.4.3.1.      JapanMarket, By Application, 2021-2030 (USD Million)

                     9.3.4.3.3.      Japan Market, By Technology, 2021-2030 (USD Million)

9.3.4.4. South Korea

                     9.3.4.4.1.      South Korea Market, By Application, 2021-2030 (USD Million)

                9.3.4.4.3.           South Korea Market, By Technology, 2021-2030 (USD Million)

9.3.4.5.             Rest of ASIA PACIFIC

                     9.3.4.5.1.      Rest of ASIA PACIFICMarket, By Application, 2021-2030 (USD Million)

                     9.3.4.5.3.      Rest of ASIA PACIFICMarket, By Technology, 2021-2030 (USD Million)

   9.4.     Latin America

              9.4.1.     Latin America Market, By Application, 2021-2030 (USD Million)

              9.4.3.     Latin America Market, By Technology, 2021-2030 (USD Million)

            9.4.4.       Latin America Market, by country, 2021-2030 (USD Million)

9.4.4.1. Brazil

                     9.4.4.1.1.      Brazil Market, By Application, 2021-2030 (USD Million)

                     9.4.4.1.3.      Brazil Market, By Technology, 2021-2030 (USD Million)

9.4.4.2. Mexico

                     9.4.4.2.1.      Mexico Market, By Application, 2021-2030 (USD Million)

            9.4.4.2.3.               Mexico Market, By Technology, 2021-2030 (USD Million)

9.4.4.3. Rest of the Latin America

                     9.4.4.3.1.      Rest of the Latin AmericaMarket, By Application, 2021-2030 (USD Million)

                     9.4.4.3.3.      Rest of the Latin AmericaMarket, By Technology, 2021-2030 (USD Million)

       9.5. MEA

              9.5.1.     MEA Market, By Application, 2021-2030 (USD Million)

              9.5.3.     MEA Market, By Technology, 2021-2030 (USD Million)

10. Competitive Landscape

10.1 Takeda Pharmaceutical Company Ltd.

              10.1.1.   Company overview

              10.1.2.   Financial performance

              10.1.3.   ProductPortfolio Analysis

              10.1.4.   Business Strategy & Recent Development

10.2. Hoffmann-La Roche Ltd.

              10.2.1.   Company overview

   10.2.2.              Financial performance

           10.2.3.      Product Portfolio Analysis

              10.2.4.   Business Strategy & Recent Development

10.3. Pfizer, Inc. 

              10.3.1.   Company overview

              10.3.2.   Financial performance

              10.3.3.   Product Portfolio Analysis

              10.3.4.   Business Strategy & Recent Development

10.4. AstraZeneca

              10.4.1.   Company overview

              10.4.2.   Financial performance

              10.4.3.   Product Portfolio Analysis

              10.4.4.   Business Strategy & Recent Development

10.5. Gilead Sciences, Inc.

              10.5.1.   Company overview

              10.5.2.   Financial performance

              10.5.3.   Product Portfolio Analysis

            10.5.4.     Business Strategy & Recent Development

10.6. Seagen, Inc.

              10.6.1.   Company overview

              10.6.2.   Financial performance

              10.6.3.   Product Portfolio Analysis

              10.6.4.   Business Strategy & Recent Development

10.7. Astellas Pharma

10.7.1.  Company overview

10.7.2.  Financial performance

              10.7.3.   Product Portfolio Analysis

              10.7.4.   Business Strategy & Recent Development

10.8. Seagen, Inc.

              10.8.1.   Company overview

              10.8.2.   Financial performance

              10.8.3.   Product Portfolio Analysis

              10.8.4.   Business Strategy & Recent Development

10.9. Daiichi Sankyo Company Ltd.

              10.9.1.   Company overview

              10.9.2.   Financial performance

              10.9.3.   Product Portfolio Analysis

              10.9.4.   Business Strategy & Recent Development

10.10. GlaxoSmithKline Plc

              10.10.1. Company overview

              10.10.2. Financial performance

              10.10.3. Product Portfolio Analysis

              10.10.4. Business Strategy & Recent Development

10.11. ADC Therapeutics

              10.11.1. Company overview

              10.11.2. Financial performance

              10.11.3. Product Portfolio Analysis

              10.11.4. Business Strategy & Recent Development

 

List of Tables (65 Tables)

TABLE 1.  Market, By Application, 2021-2030 (USD Million)

TABLE 2.  Market FOR Blood Cancer, BY REGION, 2021-2030 (USD Million)

TABLE 3.  Market FOR Breast Cancer, BY REGION, 2021-2030 (USD Million)

TABLE 4.  Market FOR Ovary Cancer, BY REGION, 2021-2030 (USD Million)

TABLE 5.  Market FOR Lung Cancer, BY REGION, 2021-2030 (USD Million)

TABLE 6.  Market FOR Skin Cancer, BY REGION, 2021-2030 (USD Million)

TABLE 7.  Market FOR Brain Tumor, BY REGION, 2021-2030 (USD Million)

TABLE 8.  Market FOR Other Applications, BY REGION, 2021-2030 (USD Million)

TABLE 9. Market, BY TECHNOLOGY, 2021-2030 (USD Million)

TABLE 10. Market FOR Cleavable Linker, BY REGION, 2021-2030 (USD Million)

TABLE 11. Market FOR Non-cleavable Linker, BY REGION, 2021-2030 (USD Million)

TABLE 12. Market FOR Linker less, BY REGION, 2021-2030 (USD Million)

TABLE 13. Market, BY REGION, 2021-2030 (USD Million)

TABLE 14. NORTH AMERICA Market, BY COUNTRY, 2021-2030 (USD Million)

TABLE 15. NORTH AMERICA Market, By Technologys, 2021-2030 (USD Million)

TABLE 16. NORTH AMERICA Market, By Application, 2021-2030 (USD Million)

TABLE 17. NORTH AMERICA Market, BY TECHNOLOGY, 2021-2030 (USD Million)

TABLE 18. EUROPE Market, BY COUNTRY, 2021-2030 (USD Million)

TABLE 19. EUROPE Market, By Application, 2021-2030 (USD Million)

TABLE 20. EUROPE Market, BY TECHNOLOGY, 2021-2030 (USD Million)

TABLE 21. ASIA-PACIFIC Market, BY COUNTRY, 2021-2030 (USD Million)

TABLE 22. ASIA-PACIFIC Market, By Application, 2021-2030 (USD Million)

TABLE 23. ASIA-PACIFIC Market, BY TECHNOLOGY, 2021-2030 (USD Million)

TABLE 24. LAMEA Market, BY COUNTRY, 2021-2030 (USD Million)

TABLE 25. LAMEA Market, By Application, 2021-2030 (USD Million)

TABLE 26. LAMEA Market, BY TECHNOLOGY, 2021-2030 (USD Million)

TABLE 27. Integra LifeSciences: COMPANY SNAPSHOT

TABLE 28. Integra LifeSciences: OPERATING SEGMENTS

TABLE 29. Kangui Medical Innovation Co. Ltd: COMPANY SNAPSHOT

TABLE 30. Kangui Medical Innovation Co. Ltd: OPERATING SEGMENTS

TABLE 31. AART Inc: COMPANY SNAPSHOT

TABLE 32. AART Inc: OPERATING SEGMENTS

TABLE 33. Anthony Products Inc: COMPANY SNAPSHOT

TABLE 35. Anthony Products Inc: OPERATING SEGMENTS

TABLE 36. Gilead Sciences, Inc.: COMPANY SNAPSHOT

TABLE 37. Gilead Sciences, Inc.: OPERATING SEGMENTS

TABLE 38. W.L. Gore & Associates, Inc: COMPANY SNAPSHOT

TABLE 39. W.L. Gore & Associates, Inc: OPERATING SEGMENTS

TABLE 40. Stryker Corporation: COMPANY SNAPSHOT

TABLE 41. Stryker Corporation: OPERATING SEGMENTS

TABLE 42. Spectrims Design Medicals Inc: COMPANY SNAPSHOT

TABLE 43. Spectrims Design Medicals Inc: OPERATING SEGMENTS

TABLE 44. Eurosurgical Ltd: COMPANY SNAPSHOT

TABLE 45. Eurosurgical Ltd: OPERATING SEGMENTS

TABLE 46. Wanhe Plastic Materials: COMPANY SNAPSHOT

TABLE 47. Wanhe Plastic Materials: OPERATING SEGMENTS

TABLE 48. Hanson Medical, Inc: COMPANY SNAPSHOT

TABLE 49. Hanson Medical, Inc: OPERATING SEGMENTS

TABLE 50. SientraIncKLS Martin L.P.: COMPANY SNAPSHOT

TABLE 51. SientraIncKLS Martin L.P.: OPERATING SEGMENTS

TABLE 52. DePuy Synthes: COMPANY SNAPSHOT

TABLE 53. DePuy Synthes: OPERATING SEGMENTS

TABLE 54. Medartis AG: COMPANY SNAPSHOT

TABLE 55. Medartis AG: OPERATING SEGMENTS

TABLE 56. Lucid Implants: COMPANY SNAPSHOT

TABLE 57. Lucid Implants: OPERATING SEGMENTS

TABLE 58. Johnson & Johnson: COMPANY SNAPSHOT

TABLE 59. Johnson & Johnson: OPERATING SEGMENTS

TABLE 60. TMJ Concepts: COMPANY SNAPSHOT

TABLE 61. TMJ Concepts: OPERATING SEGMENTS

TABLE 62. Zimmer-Biomet Inc: COMPANY SNAPSHOT

TABLE 63. Zimmer-Biomet Inc: OPERATING SEGMENTS

TABLE 64. OsteoMed: COMPANY SNAPSHOT

TABLE 65. OsteoMed: OPERATING SEGMENTS

TABLE 66. Implantech Associates, Inc: COMPANY SNAPSHOT

TABLE 67. Implantech Associates, Inc: OPERATING SEGMENTS

TABLE 68. Sebbin: COMPANY SNAPSHOT

TABLE 69. Sebbin: OPERATING SEGMENTS

 

List of Figures (20 Figures)

Figure 1 Market: Research Methodology Steps

Figure 2 Research Design

Figure 3 Breakdown of Primaries: Market

Figure 4 Research Methodology: Hypothesis Building

Figure 5 Market: Product-Based Estimation

Figure 6 Top 11 Companies with Highest No. Of Patent in Last 9 Years

Figure 7 No. Of Patents Granted Per Year, 2019–2020

Figure 8 Import Data for Antibody Drug Conjugates, By Country, 2016–2020 (USD Thousand)

Figure 9 Export Data for Antibody Drug Conjugates, By Country, 2016–2020 (USD Thousand)

Figure 10 Data Triangulation Methodology

Figure 11Market, By Technologys, 2019 vs. 2025 (USD Million)

Figure 12Market Share, By Application, 2019 vs. 2025

Figure 13 Geographical Snapshot of the Market

Figure 14 Breast Cancer to Witness Higher CAGR in Market for Product TypeSegment during Forecast Period.

Figure 15 Cleavable Linker Technology to Witness Higher CAGR in Market for Procedure Segment during Forecast Period.

Figure 16 North America Accounted for the Largest Share of the Market, By Regional Basis, in 2019

Figure 17Market: Drivers, Restraints, Opportunities, and Challenges

Figure 18 North America: Market Snapshot

Figure 19 Asia Pacific: Market Snapshot

Figure 20 Vendor Dive: Evaluation Overview

 

 

Choose License Type


$4485
$6449
$8339
Buy Now
"Click to avail the latest sample copy of the report"
Request Sample
"Probe before placing the order"
Pre-Order Enquiry
"Let's optimize your ROI by furnishing the best price"
Request Discount
"Want to curate the report according to your business needs:"
Ask for Customization
Related Reports
    Cancer Profiling Market

     Published Date :Dec-2021


    Digital Biomarkers Market

     Published Date :Jun-2022


Buy Now
Request Sample

Trust Online

  • paypal.png
  • wiretransfers

Follow Us

  • facebook
  • twitter
  • instagram
  • linkedin

Contact Us

  • US: +1-315-636-4233
  • UK: +44-162-237-0614
  • IN: +91-826-083-6500
  • info@strategicmarketresearch.com
  • Strategic Market Research
    26, Broadway Suite 934, New York , 10004

Quick Link

  • Why SMR
  • Research Methodology
  • Media Coverage
  • Join Our Team
  • Press Release
  • Blog

Customer Support

  • FAQs
  • Contact
  • Terms of Use
  • Privacy Policy
  • Disclaimer Policy
  • Return Policy
Copyright © 2022 Strategic Market Research All rights reserved.